(Q40571159)

21 September 2017

1 reference

title

Immunopathogenesis and treatment of the Guillain-Barré syndrome--Part I. (English)

1 reference

21 September 2017

main subject

Guillain–Barré syndrome

0 references

1

Hartung HP

1 reference

21 September 2017

Pollard JD

2

1 reference

21 September 2017

Harvey GK

series ordinal

3

1 reference

21 September 2017

Toyka KV

series ordinal

4

1 reference

21 September 2017

publication date

1 February 1995

1 reference

21 September 2017

1 reference

21 September 2017

volume

18

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

137-153

1 reference

Elevated neopterin levels in Guillain-Barré syndrome. Further evidence of immune activation

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FMUS.880180202

T cell activation in Guillain-Barré syndrome and in MS: elevated serum levels of soluble IL-2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMUS.880180202

Serum-mediated Schwann cell cytotoxicity in the Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMUS.880180202

Extra- and intrathecal production of antinerve and antibrain antibodies in Guillain-Barré syndrome: evaluation by an antibody index

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMUS.880180202

Antineural Antibodies in Guillain-Barre Syndrome and Lymphocytic Meningoradiculitis (Bannwarth's Syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMUS.880180202

Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré syndrome treated and not treated with plasmapheresis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMUS.880180202

21 January 2018

Identifiers

DOI

10.1002/MUS.880180202

1 reference

21 September 2017

1 reference